STERIS plc $STE Holdings Decreased by Snyder Capital Management L P

Snyder Capital Management L P lessened its stake in STERIS plc (NYSE:STE) by 1.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,368 shares of the medical equipment provider’s stock after selling 2,667 shares during the period. Snyder Capital Management L P owned 0.15% of STERIS worth $36,712,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of STERIS in the 2nd quarter worth approximately $289,132,000. Orbis Allan Gray Ltd raised its holdings in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after purchasing an additional 556,088 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in STERIS by 246.4% during the third quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock worth $137,041,000 after purchasing an additional 393,970 shares in the last quarter. Invesco Ltd. lifted its position in STERIS by 32.2% in the second quarter. Invesco Ltd. now owns 1,220,699 shares of the medical equipment provider’s stock worth $293,236,000 after purchasing an additional 297,076 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in STERIS by 305.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 330,907 shares of the medical equipment provider’s stock valued at $81,880,000 after purchasing an additional 249,386 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on STE. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

STERIS Trading Up 0.0%

Shares of STE opened at $243.37 on Thursday. The business’s 50-day moving average price is $255.21 and its 200 day moving average price is $251.70. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $23.87 billion, a P/E ratio of 33.94 and a beta of 1.05. STERIS plc has a 1-year low of $204.90 and a 1-year high of $269.44.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The firm’s revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.